Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics reported a 38% increase in Q3 revenue to $4.5 million, with a total of $12.5 million for the first nine months of 2021. Appliance sales surged by 33% in Q3, totaling 2,996 units sold. The company received FDA 510(k) clearance for its mmRNA device, enhancing reimbursement prospects. Despite a slight decrease in dentist enrollments due to COVID-19, strategic partnerships and new training facilities position Vivos for future growth. Gross margin decreased to 70% from 78% year-over-year, while cash reserves stand at $28.5 million.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q4 Virtual Investor Summit on November 17, 2021, at 11:45 am EST. The presentation features CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Investors can register for the event through the provided link and view a replay on Vivos’ website post-presentation. Vivos specializes in treatments for obstructive sleep apnea (OSA), promoting their innovative Vivos System as a non-surgical, cost-effective solution. The company has treated over 19,000 patients with their oral appliances.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its third-quarter financial results on November 15, 2021, after market close. The company will conduct a conference call at 5:00 p.m. ET on the same day to discuss the financial results and outline its growth strategy. Known for developing innovative treatments for obstructive sleep apnea, Vivos utilizes customized oral appliances in its Vivos System. The company has effectively treated over 19,000 patients globally, emphasizing its commitment to non-invasive solutions for OSA.
Vivos Therapeutics (NASDAQ: VVOS) will present at the Benzinga Global Small Cap Conference at 12:15 PM ET on October 27, 2021. The management team, including Chairman and CEO Kirk Huntsman and CFO Brad Amman, will discuss innovative treatments for mild to moderate obstructive sleep apnea (OSA) and snoring in adults. The conference runs from October 27-28, 2021. Interested investors can register for a free pass online. Vivos specializes in non-surgical treatments and has successfully treated over 19,000 patients worldwide.
Vivos Therapeutics (NASDAQ: VVOS) has announced the 3rd-annual Breathing Wellness Conference, set for October 20-23, 2021, in Las Vegas. The event aims to educate dentists and doctors about innovative treatments for patients suffering from obstructive sleep apnea (OSA) and snoring. Key speakers will discuss the implications of OSA on chronic health issues like heart disease and the latest advancements in dentofacial sleep medicine. Vivos strives to provide non-invasive solutions, differentiating itself from traditional treatments like CPAP machines.
Vivos Therapeutics (NASDAQ: VVOS) has announced a strategic collaboration with Candid Care Co. to create a comprehensive solution for diagnosing and treating obstructive sleep apnea (OSA) and providing orthodontic treatment. The partnership aims to integrate Candid's CandidPro aligner system with Vivos' innovative Vivos System. This alliance will focus on shared marketing efforts, educational resources, and specialized training to enhance patient outcomes. Both companies expect to increase market penetration and drive revenue growth through this collaboration, tapping into existing dental and healthcare networks in the U.S. and Canada.
Vivos Therapeutics (NASDAQ: VVOS) announced a collaboration with Candid Care to offer a comprehensive solution for obstructive sleep apnea (OSA) and orthodontic treatments. This partnership aims to combine Candid's clear aligners with Vivos' OSA treatment system, enhancing patient outcomes. The agreement includes joint marketing efforts, shared educational resources, and exploration of new research opportunities. The collaboration is expected to boost market penetration and revenue growth for both companies across North America.
Vivos Therapeutics (NASDAQ: VVOS) announced significant findings from a peer-reviewed study on its FDA-registered Vivos Guide, an intraoral device aimed at reducing pediatric tooth decay.
The study, led by Dr. Toshi Hart, demonstrated a 76.4% reduction in tooth decay risk at six months and 57.9% at twelve months for children using the device compared to a control group. The device encourages nasal breathing over mouth breathing, potentially increasing salivary factors that combat tooth decay.
Vivos Therapeutics (NASDAQ: VVOS) has established the Vivos Medical Consortium to enhance research in managing obstructive sleep apnea (OSA). Co-chaired by Dr. Clete Kushida from Stanford and Dr. Cecilia Wu from the University of Alberta, the consortium comprises specialists from various medical fields. The group's goal is to improve physician-dental collaboration and explore new applications for Vivos' OSA technology, which has shown promising results. Vivos aims to facilitate broader adoption of its innovative, non-invasive therapies for patients with OSA.
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a company focused on innovative treatments for sleep-disordered breathing, will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 2:20 pm EST. The presentation will be led by Chairman Kirk Huntsman and CFO Brad Amman. Interested investors can register for a free spectator pass. Vivos offers non-surgical solutions for obstructive sleep apnea through its Vivos System, which has helped over 19,000 patients globally. A replay will be available on their website post-event.